Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Barclays analyst Balaji Prasad maintains Evolus (NASDAQ:EOLS) with a Overweight and raises the price target from $16 to $20.
Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $22 price target.
Cantor Fitzgerald analyst Louise Chen reiterates Evolus (NASDAQ:EOLS) with a Overweight.
HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $27 price target.
Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $22 price target.
Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 ...
The company continues to expect its adjusted gross profit margin for the full year 2024 to be between 68% and 71%. The compa...
Launching into this growth market1 as part of the company's geographic expansion strategyEvolus Australia established to dr...
